Immunother Limited today announced that they will enter into a strategic research and development partnership that will specialize in 3D tissue regeneration.
Online PR News – 21-September-2021 – SHENZHEN – Immunother Limited will integrate their systems technologies with the Korean company and together, they both have the vision to enable cellular-level assessments into 3D-bioprinting to create human tissue models.
Immunother Limited’s Chairman & Chief Scientist, Mr. Geoffrey Marcus PhD commented on the new partnership saying “This new partnership would allow us and our partners’ scientists and tissue engineers to quickly design and build and vascularized 3D tissues in a single and streamlined process and both of our technologies will enable the 3D bioprinted micro-vessels to self-assemble into functional capillary beds which will deliver nutrients, oxygen, and hormones to the 3D tissue sample model and remove waste.”
“Printing multi-material 3D objects will allow scientists to efficiently move away from traditional 2D monocultures on plastic, to 3D discovery and cytotoxicity models that more accurately reflect the human body’s native biology and immune systems. By combining our knowledge, we both have the desire to develop of a confocal screening platform with the vision of high content screening in 3D models to become a reality,” added Geoffrey Marcus, Chairman & Chief Scientist of Immunother Limited.
About Us - Immunother Limited
Immunother Limited Company is a privately held Shenzhen-based preclinical stage biotechnology company focused on discovering and developing novel therapies for inflammatory diseases.
Immunother Limited Company creates lasting value through pioneering research in the field of immunology which leads to new product concepts, product development, and finally to the licensing of those products and associated intellectual property.